Ardelyx Inc.

225 articles about Ardelyx Inc.

• Ardelyx Inc. Appoints Dr. Annalisa Jenkins To Its Board Of Directors

  4/20/2015

• Ardelyx Inc. To Present At The 22nd Annual Future Leaders In The Biotech Industry Conference

  3/13/2015

• Ardelyx Inc. Reports Fourth Quarter and Full Year 2014 Financial Results

  2/26/2015

• Ardelyx Inc. To Report Fourth Quarter And Full Year 2014 Financial Results On February 25th, 2015

  2/18/2015

• Ardelyx Inc. To Present At The 2015 Leerink Global Healthcare Conference

  2/9/2015

• Ardelyx Inc. Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor In Treating Hyperphosphatemia In Chronic Kidney Disease Patients On Hemodialysis

  2/2/2015

• Ardelyx Inc. Appoints Jeremy S. Caldwell, Ph.D., As Executive Vice President And Chief Scientific Officer

  12/1/2014

• Ardelyx Inc.'s Tenapanor Reduces Phosphorus Absorption And Protects Against Vascular Calcification In Preclinical In Vivo Model Of Chronic Kidney Disease

  11/17/2014

• Ardelyx Inc. Reports Third Quarter 2014 Financial Results

  11/6/2014

• Ardelyx Inc. To Report Third Quarter 2014 Financial Results On November 6, 2014

  10/30/2014

• Ardelyx Inc.'s Tenapanor Selected For Oral And Poster Presentations At The American Society of Nephrology's Kidney Week 2014

  10/23/2014

• Ardelyx Inc. Looks Good After Tenanpanor Results: Citi Analysts

  10/1/2014

• Ardelyx Inc. Irritable Bowel Syndrome Drug Succeeds In Phase 2b Trial

  10/1/2014

• Ardelyx Inc. Chief Scientific Officer, Dominique Charmot, Announces Retirement From The Company At Year-End

  9/5/2014

• Ardelyx Inc. To Present At The Wedbush 2014 Life Sciences Management Access Conference

  8/5/2014

• Ardelyx Inc. Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

  6/25/2014

• Fremont Biotech Ardelyx Inc. Prices IPO At $14 Per Share

  6/19/2014

• Bay Area's Ardelyx Inc. Lowers IPO Target Slightly, Now Hopes To Raise Up To $62 Million

  6/11/2014

• Fremont-Based Ardelyx Inc. Files For $69 Million IPO

  5/22/2014

• Ardelyx Inc. Receives $25 Million Milestone From AstraZeneca PLC For Commencement Of Phase 2b Clinical Trial Of Tenapanor

  5/15/2014